Show simple item record

dc.contributor.authorHammerschlag, M R
dc.contributor.authorQumei, K K
dc.contributor.authorRoblin, P M
dc.date.accessioned2023-06-29T15:41:26Z
dc.date.available2023-06-29T15:41:26Z
dc.date.issued1992-07
dc.identifier.citationHammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573. PMID: 1324650; PMCID: PMC191624.en_US
dc.identifier.issn0066-4804
dc.identifier.pmid1324650
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10329
dc.description.abstractThe in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycline were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chlamydiacidal concentration for 90% of strains of 0.03 microns/ml. The activity of azithromycin was similar to those of erythromycin and doxycycline, with MICs for 90% of strains of 0.125 to 0.25 microns/ml. However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin. L-Ofloxacin had activity similar to that of ofloxacin, with MICs of 0.125 to 0.5 micron/ml. From the results of this in vitro study, azithromycin and clarithromycin appear to be effective antibiotics that may have a role in the treatment of infections due to C. pneumoniae.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epdf/10.1128/aac.36.7.1573en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIn vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume36
dc.source.issue7
dc.source.beginpage1573
dc.source.endpage4
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-06-29T15:41:28Z
html.description.abstractThe in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycline were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chlamydiacidal concentration for 90% of strains of 0.03 microns/ml. The activity of azithromycin was similar to those of erythromycin and doxycycline, with MICs for 90% of strains of 0.125 to 0.25 microns/ml. However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin. L-Ofloxacin had activity similar to that of ofloxacin, with MICs of 0.125 to 0.5 micron/ml. From the results of this in vitro study, azithromycin and clarithromycin appear to be effective antibiotics that may have a role in the treatment of infections due to C. pneumoniae.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy
dc.identifier.issue7en_US


Files in this item

Thumbnail
Name:
aac.36.7.1573.pdf
Size:
389.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International